首页 工具
登录
购物车
Z-VAD-FMK

Z-VAD-FMK

产品编号 T7020   CAS 161401-82-7
别名: Z-VAD(OH)-FMK, Caspase Inhibitor VI, Z-VAD

Z-VAD-FMK (Caspase Inhibitor VI) 是一种不可逆的泛半胱天冬酶抑制剂。

TargetMol的所有产品和服务仅用于科学研究,不能被用于人体,我们也不向个人提供产品和服务。
Z-VAD-FMK Chemical Structure
Z-VAD-FMK, CAS 161401-82-7
规格 价格/CNY 货期 数量
1 mg ¥ 698 现货
5 mg ¥ 2,551 现货
10 mg ¥ 3,170 现货
25 mg ¥ 5,200 现货
1 mL * 10 mM (in DMSO) ¥ 2,555 现货
产品目录号及名称: Z-VAD-FMK (T7020)
点击图片重新获取验证码
选择批次  
纯度: 99.44%
纯度: 98.63%
纯度: 98.24%
更多批次查询请联系客服
生物活性
化学信息
存储 & 溶解度
参考文献
产品描述 Z-VAD-FMK (Caspase Inhibitor VI) is an irreversible pan-caspase inhibitor.
体外活性 Z-VAD(OH)-FMK is the non-methylated form of Z-VAD-FMK, and useful in studies including recombinant, or purified enzymes. [1]
别名 Z-VAD(OH)-FMK, Caspase Inhibitor VI, Z-VAD
分子量 453.46
分子式 C21H28FN3O7
CAS No. 161401-82-7

存储

Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度

H2O: <1 mg/mL

Ethanol: 83 mg/mL (183 mM)

DMSO: 83 mg/mL (183 mM)

溶液配制表

可选溶剂 浓度 体积 质量 1 mg 5 mg 10 mg 25 mg
Ethanol / DMSO 1 mM 2.2053 mL 11.0263 mL 22.0527 mL 55.1317 mL
5 mM 0.4411 mL 2.2053 mL 4.4105 mL 11.0263 mL
10 mM 0.2205 mL 1.1026 mL 2.2053 mL 5.5132 mL
20 mM 0.1103 mL 0.5513 mL 1.1026 mL 2.7566 mL
50 mM 0.0441 mL 0.2205 mL 0.4411 mL 1.1026 mL
100 mM 0.0221 mL 0.1103 mL 0.2205 mL 0.5513 mL

计算器

摩尔浓度计算器
稀释计算器
配液计算器
分子量计算器
=
X
X
X
=
X
=
/
g/mol

输入分子式,点击计算,可计算出产品的分子量。

参考文献

1. Garcia-Calvo M, et al. J Biol Chem. 1998, 273(49), 32608-32613. 2. Xue J, Gruber F, Tschachler E, et al. Crosstalk between oxidative stress, autophagy and apoptosis in Hemoporfin Photodynamic Therapy treated human umbilical vein endothelial cells[J]. Photodiagnosis and Photodynamic Therapy. 2020: 102137. 3. Sun Y, He L, Wang T, et al. Activation of p62-Keap1-Nrf2 Pathway Protects 6-Hydroxydopamine-Induced Ferroptosis in Dopaminergic Cells[J]. Molecular Neurobiology. 2020, 57(11): 4628-4641.

文献引用

1. Yan C, Zheng L, Jiang S, et al.Exhaustion-associated cholesterol deficiency dampens the cytotoxic arm of antitumor immunity.Cancer Cell.2023 2. Hu G, Cui Z, Chen X, et al.Suppressing Mesenchymal Stromal Cell Ferroptosis Via Targeting a Metabolism‐Epigenetics Axis Corrects their Poor Retention and Insufficient Healing Benefits in the Injured Liver Milieu.Advanced Science.2023: 2206439. 3. Wang X, Ji Y, Qi J, et al.Mitochondrial carrier 1 (MTCH1) governs ferroptosis by triggering the FoxO1-GPX4 axis-mediated retrograde signaling in cervical cancer cells.Cell Death & Disease.2023, 14(8): 1-13. 4. Zhu X, Huang N, Ji Y, et al.Brusatol induces ferroptosis in oesophageal squamous cell carcinoma by repressing GSH synthesis and increasing the labile iron pool via inhibition of the NRF2 pathway.Biomedicine & Pharmacotherapy.2023, 167: 115567. 5. Qiu C, Shen X, Lu H, et al.Combination therapy with HSP90 inhibitors and piperlongumine promotes ROS-mediated ER stress in colon cancer cells.Cell Death Discovery.2023, 9(1): 375. 6. Huang F, Liang J, Lin Y, et al.Repurposing of Ibrutinib and Quizartinib as potent inhibitors of necroptosis.Communications Biology.2023, 6(1): 972. 7. Shao H, Xu L, Li G, et al.Analysis on benzothiazole necroptosis inhibitors with chiral substitutions in the solvent-accessible region of RIP kinase domain.Bioorganic Chemistry.2023: 106647. 8. Zeng H, Xie H, Ma Q, et al.Identification of N-(3-(methyl (3-(orotic amido) propyl) amino) propyl) oleanolamide as a novel topoisomerase I catalytic inhibitor by rational design, molecular dynamics simulation, and biological evaluation.Bioorganic Chemistry.2023: 106734. 9. Sun Y, Xu L, Shao H, et al. Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease. Journal of Medicinal Chemistry. 2022 10. Xue J, Gruber F, Tschachler E, et al. Crosstalk between oxidative stress, autophagy and apoptosis in Hemoporfin Photodynamic Therapy treated human umbilical vein endothelial cells. Photodiagnosis and Photodynamic Therapy. 2020: 102137.
11. Su G, Yang W, Wang S, et al. SIRT1-autophagy axis inhibits excess iron-induced ferroptosis of foam cells and subsequently increases IL-1Β and IL-18. Biochemical and Biophysical Research Communications. 2021, 561: 33-39. 12. Ning X, Qi H, Yuan Y, et al. Identification of a new small molecule that initiates ferroptosis in cancer cells by inhibiting the system Xc− to deplete GSH. European Journal of Pharmacology. 2022: 175304. 13. Wang F, Xie M, Chen P, et al. Homoharringtonine combined with cladribine and aclarubicin (HCA) in acute myeloid leukemia: A new regimen of conventional drugs and its mechanism. Oxidative Medicine and Cellular Longevity. 2022 14. Wang S, Wang Z, Wang X, et al. Humanized cerebral organoids-based ischemic stroke model for discovering of potential anti-stroke agents. Acta Pharmacologica Sinica. 2022: 1-11. 15. Sun Y, He L, Wang T, et al. Activation of p62-Keap1-Nrf2 Pathway Protects 6-Hydroxydopamine-Induced Ferroptosis in Dopaminergic Cells. Molecular Neurobiology. 2020, 57(11): 4628-4641. 16. Tschuck J, Theilacker L, Rothenaigner I, et al.Farnesoid X receptor activation by bile acids suppresses lipid peroxidation and ferroptosis.Nature Communications.2023, 14(1): 6908. 17. Tian T, Xie X, Yi W, et al.FBXO38 mediates FGL1 ubiquitination and degradation to enhance cancer immunity and suppress inflammation.Cell Reports.2023, 42(11). 18. Wu X, Yi X, Zhao B, et al.The volume regulated anion channel VRAC regulates NLRP3 inflammasome by modulating itaconate efflux and mitochondria function.Pharmacological Research.2023: 107016. 19. Liu S, Tao Y, Wu S, et al.Sanguinarine chloride induces ferroptosis by regulating ROS/BACH1/HMOX1 signaling pathway in prostate cancer.Chinese Medicine.2024, 19(1): 1-18. 20. Chen H, Hu J, Xiong X, et al.AURKA inhibition induces Ewing’s sarcoma apoptosis and ferroptosis through NPM1/YAP1 axis.Cell Death & Disease.2024, 15(1): 99. 21. Tao Y, Lu J, Li L, et al.Raltitrexed induces apoptosis through activating ROS-mediated ER stress by impeding HSPA8 expression in prostate cancer cells.Biochimica et Biophysica Acta (BBA)-Molecular Cell Research.2024: 119684. 22. Li J, Liu X, Liu Y, et al.Saracatinib inhibits necroptosis and ameliorates psoriatic inflammation by targeting MLKL.Cell Death & Disease.2024, 15(2): 122.
收起
View product citations for antibody PRODUCT_CODE on CiteAb
Ac-YVAD-CMK Dehydrotrametenolic acid Taurohyodeoxycholic acid sodium salt BOC-D-FMK Formosanin C Soyasaponin Bb Griffipavixanthone Thevetiaflavone

相关化合物库

该产品包含在如下化合物库中:
高选择性抑制剂库 抗衰老化合物库 经典已知活性库 抗癌化合物库 已知活性化合物库 NO PAINS 化合物库

剂量换算

对于不同动物的给药剂量换算,您也可以参考 更多...

体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。

第一步:请输入动物实验的基本信息
剂量
mg/kg
每只动物体重
g
给药体积
μL
动物数量
第二步:请输入动物体内配方组成,不同的产品配方组成不同,如有配方需求,可先联系我们提供正确的体内配方。
% DMSO
%
% Tween 80
% ddH2O
计算 重置

技术支持

您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。

Keywords

Z-VAD-FMK 161401-82-7 Apoptosis Proteases/Proteasome Caspase inhibit Inhibitor ZVADFMK Hela Z VAD FMK Antiapoptosis cells pan-caspase Z-VAD(OH)-FMK Caspase Inhibitor VI Z-VAD inhibitor

 

陶术
生物
TargetMol®中国区唯一合作伙伴
点击进入陶术生物官网陶术生物
联系我们
400-820-0310

上海市静安区江场三路238号8楼